James G. Bender
Nessuna posizione attualmente
Profilo
James G.
Bender worked as a Director of Product Development at IDM Pharma, Inc. from 2002 to 2008.
He then worked as a Vice President of Product Development and Manufacturing at ImmunoCellular Therapeutics Ltd.
from 2008 to 2014.
After that, he worked as a VP of Product Development and Manufacturing at Iovance Biotherapeutics, Inc. Dr. Bender holds a graduate degree from the University of Michigan and a doctorate degree from The University of New Mexico.
Precedenti posizioni note di James G. Bender
| Società | Posizione | Fine |
|---|---|---|
| EOM PHARMACEUTICALS HOLDINGS, INC. | Corporate Officer/Principal | 03/01/2014 |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2008 |
| IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formazione di James G. Bender
| The University of New Mexico | Doctorate Degree |
| University of Michigan | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
ImmunoCellular Therapeutics Ltd.
 ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- James G. Bender
